Urticaria and Angioedema Associated with Fluoxetine.
Clinical Psychopharmacology and Neuroscience.2017;15(4):418-419. doi:10.9758/cpn.2017.15.4.418
Clinical Psychopharmacology and Neuroscience
2002 (v1, n1) to Present ISSN: 1671-8925
Year of publication
Sort by
DISPLAY OPTIONS
Format:
Per page:
High Dose Ofloxacin-induced Bimodal Hallucinations in a 4 Years Old Child.
Clinical Psychopharmacology and Neuroscience.2017;15(4):416-417. doi:10.9758/cpn.2017.15.4.416
Ofloxacin is a commonly used quinolone antibiotic both in adults as well as children. It is generally safe and well tolerated. Rarely, neurological and psychiatric adverse reactions are reported to occur with ofloxacin. We report a case of a child who developed delirium after ofloxacin treatment, that resolved after medication discontinuation and treatment with low dose olanzapine.
Adult ; Child* ; Delirium ; Hallucinations* ; Humans ; Ofloxacin ; Psychotic Disorders
Adult ; Child* ; Delirium ; Hallucinations* ; Humans ; Ofloxacin ; Psychotic Disorders
Neutropenia with Multiple Antipsychotics Including Dose Dependent Neutropenia with Lurasidone.
Clinical Psychopharmacology and Neuroscience.2017;15(4):413-415. doi:10.9758/cpn.2017.15.4.413
Antipsychotic-induced agranulocytosis is a significant side effect that is known to occur with most of the antipsychotic medications. It usually resolves once the medications are stopped and patients are able to be switched over to another antipsychotic medication. Lurasidone has not been reported to cause leukopenia and neutropenia. This case report is of a patient with a past history of risperidone induced-aganulocytosis developing dose related leukopenia and neutropenia with lurasidone.
Agranulocytosis ; Antipsychotic Agents* ; Humans ; Leukopenia ; Lurasidone Hydrochloride* ; Neutropenia* ; Risperidone
Agranulocytosis ; Antipsychotic Agents* ; Humans ; Leukopenia ; Lurasidone Hydrochloride* ; Neutropenia* ; Risperidone
Clinical Psychopharmacology and Neuroscience.2017;15(4):410-412. doi:10.9758/cpn.2017.15.4.410
Our case had hiccups arising in an adolescent with the attention deficit and hyperactivity disorder (ADHD) and conduct disorder (CD) after adding aripiprazole treatment to extended-release methylphenidate. Actually, antipsychotics are also used in the treatment of hiccups, but studies suggest that they can cause hiccups as well. Within 12 hours of taking 2.5 mg aripiprazole added to extended-release methylphenidate at a dose of 54 mg/day, 16-year-old boy began having hiccups in the morning, which lasted after 3–4 hours. As a result, aripiprazole was discontinued and methylphenidate was continued alone because we could not convince the patient to use another additional drug due to this side effect. Subsequently, when his behavior got worsened day by day, his mother administered aripiprazole alone again at the dose of 2.5 mg/day at the weekend and continued treatment because hiccup did not occur again. But when it was administered with methylphenidate on Monday, hiccup started again next morning and lasted one hour at this time. In conclusion, we concluded that concurrent use of methylphenidate and aripiprazole in this adolescent led to hiccups.
Adolescent* ; Antipsychotic Agents ; Aripiprazole* ; Conduct Disorder* ; Cytochrome P-450 CYP2D6 ; Hiccup* ; Humans ; Male ; Methylphenidate* ; Mothers
Adolescent* ; Antipsychotic Agents ; Aripiprazole* ; Conduct Disorder* ; Cytochrome P-450 CYP2D6 ; Hiccup* ; Humans ; Male ; Methylphenidate* ; Mothers
Lithium Intoxication: A Possible Interaction with Moxifloxacin.
Clinical Psychopharmacology and Neuroscience.2017;15(4):407-409. doi:10.9758/cpn.2017.15.4.407
Lithium is a well-known treatment for patients with mood disorders. Intoxication by lithium may be lethal particularly in elderly due to altered pharmacokinetics, renal impairment or multiple drug use. We presented a 74-year-old female patient who had been stabile with lithium carbonate 600 mg/day for 5 years and developed lithium intoxication after bronchiolitis. She presented with altered mental status. The neurological signs resolved slowly after lithium and moxifloxacin were stopped immediately and fluid resuscitation administered. Considering possible drug interactions on elderly patients receiving lithium is essential.
Aged ; Bronchiolitis ; Drug Interactions ; Female ; Humans ; Lithium Carbonate ; Lithium* ; Mood Disorders ; Pharmacokinetics ; Resuscitation
Aged ; Bronchiolitis ; Drug Interactions ; Female ; Humans ; Lithium Carbonate ; Lithium* ; Mood Disorders ; Pharmacokinetics ; Resuscitation
Clinical Psychopharmacology and Neuroscience.2017;15(4):402-406. doi:10.9758/cpn.2017.15.4.402
OBJECTIVE: Recent studies have reported associations of retinoid-related orphan receptor alpha (RORA) gene single nucleotide polymorphisms (SNPs) with depression and anxiety disorders. Based on these, we attempt to test whether RORA polymorphism is associated with anxiety sensitivity (AS), the intermediate phenotype of depression and anxiety disorders. Considering gene-environment interactions and sex differences in AS, childhood maltreatment (CM) and sex were considered as confounders. METHODS: Two-hundred and five healthy young Korean adults (female: 98, male: 107; age, 23.0±3.2 years) completed genotyping for the RORA SNP rs11071547, as well as measures for AS and CM. Generalized linear models were used to examine the main and interaction effects of RORA genotype, CM, and sex in determining AS. RESULTS: The main effect of RORA polymorphisms was not found (p=0.760) whereas the main effect of CM and interaction effects among sex, genotype, and maltreatment were significant on AS. In separate analyses by sex, the interaction effect between RORA genotype and maltreatment was significant only in males (p < 0.001). In females, the main effects of genotype and CM were significant (both were p < 0.001), in which both a history of CM and C genotype tended to be associated with higher AS. CONCLUSION: The association between RORA polymorphism and AS might differ by sex. The interaction between RORA polymorphism and CM was significant only in males whereas RORA genotype and CM independently associated with AS in females. Further studies are encouraged to confirm the relationship between RORA polymorphism and AS.
Adult ; Anxiety Disorders ; Anxiety* ; Child ; Child, Orphaned ; Depression ; Female ; Gene-Environment Interaction ; Genotype ; Humans ; Linear Models ; Male ; Phenotype ; Polymorphism, Single Nucleotide ; Sex Characteristics ; Young Adult*
Adult ; Anxiety Disorders ; Anxiety* ; Child ; Child, Orphaned ; Depression ; Female ; Gene-Environment Interaction ; Genotype ; Humans ; Linear Models ; Male ; Phenotype ; Polymorphism, Single Nucleotide ; Sex Characteristics ; Young Adult*
Clinical Psychopharmacology and Neuroscience.2017;15(4):391-401. doi:10.9758/cpn.2017.15.4.391
OBJECTIVE: The purpose of this study was to compare the efficacy and safety of escitalopram, paroxetine and venlafaxine in Korean patients with major depressive disorder (MDD). METHODS: A total of 449 Korean MDD patients were recruited in a six-week, randomized, rater-blinded, active-controlled trial and were evenly randomized to paroxetine, venlafaxine, or escitalopram treatment. RESULTS: When comparing the mean difference for the Montgomery-Åsberg Depression Rating Scale (MADRS) and the Hamilton Depression Rating Scale (HDRS) total scores during six weeks, paroxetine (−6.4±0.4, and −5.4±0.4, respectively) was found to be significantly superior to escitalopram (−3.7±0.5 and −3.1±0.4, respectively). Venlafaxine had a significantly lower MADRS total score (−5.4±0.4) than escitalopram. When adjusting baseline variables, the response, according to the MADRS and HDRS scores, in the paroxetine group was greater than that for the escitalopram group (odds ratio [OR]=2.43, 95% confidence interval [CI]=1.42–4.16 for MADRS; and OR=2.32, 95% CI=1.35–3.97 for HDRS) and the venlafaxine group (OR=1.94, 95% CI=1.17–3.21 for MADRS; and OR=1.71, 95% CI=1.03–2.83 for HDRS). Despite that the overall tolerability was high and similar among the three groups, a total of 268 subjects (59.7%) prematurely discontinued treatment, representing the main limitation of the present study. CONCLUSION: Although a low study completion rate limits generalizability, our findings suggest that paroxetine might be superior to escitalopram in Korean MDD patients. Further studies should be conducted to draw a definite conclusion.
Citalopram* ; Depression ; Depressive Disorder, Major* ; Humans ; Paroxetine* ; Venlafaxine Hydrochloride*
Citalopram* ; Depression ; Depressive Disorder, Major* ; Humans ; Paroxetine* ; Venlafaxine Hydrochloride*
Clinical Psychopharmacology and Neuroscience.2017;15(4):382-390. doi:10.9758/cpn.2017.15.4.382
OBJECTIVE: In this study, we investigated the determinants of remission and discontinuation of paroxetine pharmacotherapy in outpatients with panic disorder (PD). METHODS: Subjects were 79 outpatients diagnosed with PD who took 10–40 mg/day of paroxetine for 12 months. The candidate therapeutic determinants included the serotonin transporter gene-linked polymorphic region and the −1019C/G promoter polymorphism of the serotonin receptor 1A as genetic factors, educational background and marital status as environmental factors, and early improvement (EI) at 2 weeks as a clinical factor were assessed. The Clinical Global Impression scale was used to assess the therapeutic effects of the pharmacotherapy. RESULTS: Cox proportional hazards regression was performed to investigate the significant predictive factors of remission and discontinuation. EI was only a significant predictive factor of remission. EI was a significant predictive factor of remission (hazard ratio [HR], 2.709; 95% confidence interval [CI], 1.177–6.235). Otherwise, EI and marital status were significant predictive factors of the discontinuation. EI (HR, 0.266; 95% CI, 0.115–0.617) and being married (HR, 0.437; 95% CI, 0.204–0.939) were considered to reduce the risk of treatment discontinuation. In married subjects, EI was a significant predictive factor of the discontinuation (HR, 0.160; 95% CI, 0.045–0.565). However, in unmarried subjects, EI was not a significantly predictive factor for the discontinuation. CONCLUSION: EI achievement appears to be a determinant of PD remission in paroxetine treatment. In married PD patients, EI achievement also appears to reduce a risk of discontinuation of paroxetine treatment.
Drug Therapy ; Humans ; Marital Status ; Marriage* ; Outpatients* ; Panic Disorder* ; Panic* ; Paroxetine* ; Patient Dropouts ; Remission Induction ; Serotonin ; Serotonin Plasma Membrane Transport Proteins ; Single Person ; Therapeutic Uses ; Treatment Outcome*
Drug Therapy ; Humans ; Marital Status ; Marriage* ; Outpatients* ; Panic Disorder* ; Panic* ; Paroxetine* ; Patient Dropouts ; Remission Induction ; Serotonin ; Serotonin Plasma Membrane Transport Proteins ; Single Person ; Therapeutic Uses ; Treatment Outcome*
Clinical Psychopharmacology and Neuroscience.2017;15(4):369-381. doi:10.9758/cpn.2017.15.4.369
OBJECTIVE: In the current study we investigated neurodevelopmental changes in response to social and non-social reinforcement. METHODS: Fifty-three healthy participants including 16 early adolescents (age, 10–15 years), 16 late adolescents (age, 15–18 years), and 21 young adults (age, 21–25 years) completed a social/non-social reward learning task while undergoing functional magnetic resonance imaging. Participants responded to fractal image stimuli and received social or non-social reward/non-rewards according to their accuracy. ANOVAs were conducted on both the blood oxygen level dependent response data and the product of a context-dependent psychophysiological interaction (gPPI) analysis involving ventromedial prefrontal cortex (vmPFC) and bilateral insula cortices as seed regions. RESULTS: Early adolescents showed significantly increased activation in the amygdala and anterior insula cortex in response to non-social monetary rewards relative to both social reward/non-reward and monetary non-rewards compared to late adolescents and young adults. In addition, early adolescents showed significantly more positive connectivity between the vmPFC/bilateral insula cortices seeds and other regions implicated in reinforcement processing (the amygdala, posterior cingulate cortex, insula cortex, and lentiform nucleus) in response to non-reward and especially social non-reward, compared to late adolescents and young adults. CONCLUSION: It appears that early adolescence may be marked by: (i) a selective increase in responsiveness to non-social, relative to social, rewards; and (ii) enhanced, integrated functioning of reinforcement circuitry for non-reward, and in particular, with respect to posterior cingulate and insula cortices, for social non-reward.
Adolescent ; Amygdala ; Fractals ; Gyrus Cinguli ; Healthy Volunteers ; Humans ; Learning ; Magnetic Resonance Imaging* ; Oxygen ; Prefrontal Cortex ; Reinforcement, Social* ; Reward ; Young Adult
Adolescent ; Amygdala ; Fractals ; Gyrus Cinguli ; Healthy Volunteers ; Humans ; Learning ; Magnetic Resonance Imaging* ; Oxygen ; Prefrontal Cortex ; Reinforcement, Social* ; Reward ; Young Adult
Clinical Psychopharmacology and Neuroscience.2017;15(4):361-368. doi:10.9758/cpn.2017.15.4.361
OBJECTIVE: Several studies have suggested the efficacy of bupropion and escitalopram on reducing the excessive internet game play. We hypothesized that both bupropion and escitalopram would be effective on reducing the severity of depressive symptoms and internet gaming disorder (IGD) symptoms in patients with both major depressive disorder and IGD. However, the changes in brain connectivity between the default mode network (DMN) and the salience network were different between bupropion and escitalopram due to their different pharmacodynamics. METHODS: This study was designed as a 12-week double blind prospective trial. Thirty patients were recruited for this research (15 bupropion group+15 escitalopram group). To assess the differential functional connectivity (FC) between the hubs of the DMN and the salience network, we selected 12 regions from the automated anatomical labeling in PickAtals software. RESULTS: After drug treatment, the depressive symptoms and IGD symptoms in both groups were improved. Impulsivity and attentional symptoms in the bupropion group were significantly decreased, compared to the escitalopram group. After treatment, FC within only the DMN in escitalopram decreased while FC between DMN and salience network in bupropion group decreased. Bupropion was associated with significantly decreased FC within the salience network and between the salience network and the DMN, compared to escitalopram. CONCLUSION: Bupropion showed greater effects than escitalopram on reducing impulsivity and attentional symptoms. Decreased brain connectivity between the salience network and the DMN appears to be associated with improved excessive IGD symptoms and impulsivity in MDD patients with IGD.
Brain ; Bupropion* ; Citalopram* ; Depression ; Depressive Disorder, Major* ; Humans ; Immunoglobulin D ; Impulsive Behavior ; Internet* ; Magnetic Resonance Imaging ; Prospective Studies ; Video Games
Brain ; Bupropion* ; Citalopram* ; Depression ; Depressive Disorder, Major* ; Humans ; Immunoglobulin D ; Impulsive Behavior ; Internet* ; Magnetic Resonance Imaging ; Prospective Studies ; Video Games
Country
Republic of Korea
Publisher
Korean College of Neuropsychopharmacology
ElectronicLinks
http://www.cpn.or.kr/Editor-in-chief
Young-Chul Chung
secretariat@kcnp.or.kr
Abbreviation
Clin Psychopharmacol Neurosci
Vernacular Journal Title
ISSN
1738-1088
EISSN
2093-4327
Year Approved
2012
Current Indexing Status
Currently Indexed
Start Year
2003
Description
Powered by IMICAMS(
备案号: 11010502037788, 京ICP备10218182号-8)